introduction
over 400 million, including 34 million children, live with disabling hearing loss, affecting their health and quality of life. hearing loss is a common hearing disorder disease with high occurrence and complex causes. genetic factors are responsible for over 50% of hearing loss encountered in neonates, and account for nearly 40% of childhood hearing loss.
bgi have established a neonatal hearing screening strategy combined with genetic test for early detection of hereditary deafness by collecting microscopic blood samples from newborns and extracting dna for high-throughput sequencing. the risk of hearing impairment in newborns will assessed by combining bioinformatics analysis.
optional panel suitable for
option 1: newborns pregnant couples with normal phenotype； option 2: deafness or hearing loss patient population with a family history of deafness or hearing loss
sample
dbs; blood
technology
target sequencing
why choose bgi nova™ newborn hereditary hearing loss screening?
- avoiding drug-induced hearing loss
- avoiding late-onset hearing loss
- predicting the outcome of ci
- early detecton and early intervention